另外，今年3月，相关部门依法对甲硫酸新斯的明注射液垄断案涉嫌企业罚没合计2.23亿元，并首次对有 关人员追究达成垄断协议的个人责任。 来源：北京日报 6月13日召开的市场监管总局2025年二季度例行新闻发布会，公布两起医药领域反垄断执法案例。其中 地塞米松磷酸钠原料药垄断案中，四企业通过共同涨价，将原料药销售价格从每公斤8000元上涨到1.3万 元，相关部门对组织垄断协议的自然人、涉案企业及负有责任的人员分别处以罚款，罚没合计3.62亿元。 近日，根据总局指定管辖，天津市市场监管委依法对郭某某组织津药药业股份有限公司、浙江仙琚制药股 份有限公司、江苏联环药业股份有限公司和西安国康瑞金制药有限公司四家企业达成并实施垄断协议案作 出行政处罚。 经查，2021年11月起，自然人郭某某通过沟通联络、组织聚会、实地走访等方式，与四家企业相关人员 商讨提高地塞米松磷酸钠原料药价格，达成停止价格竞争、共同涨价的协议，四家企业随后同步停止对外 供货，造成市场供应紧张，并按照协议共同提高价格。2022年2月至2024年3月，四家企业将地塞米松磷 酸钠原料药销售价格从每公斤8000元上涨到1.3万元，排除、限制了市场竞争，进一步 ...

Group 1 - The case involves administrative penalties against four pharmaceutical companies for reaching and implementing a monopoly agreement regarding the price of dexamethasone phosphate raw materials, violating the Anti-Monopoly Law of the People's Republic of China [2][4] - The penalties highlight a significant shift in anti-monopoly enforcement in China, extending legal responsibility from corporate entities to individuals, marking a breakthrough in combating monopolistic behavior [1][5][10] - The raw material in question, dexamethasone, is crucial for producing injections used in treating various inflammatory diseases and has been included in treatment protocols for severe COVID-19 cases, indicating its importance in public health [3][4] Group 2 - The enforcement action against the individual organizer of the monopoly agreement represents a notable development in anti-monopoly law, emphasizing the legal accountability of individuals in addition to corporations [5][10] - The case demonstrates the potential for significant market distortion when companies collude to fix prices, which can adversely affect drug accessibility and pricing for consumers [3][4][10] - The penalties imposed on the individual organizer, amounting to 5 million yuan, reflect the law's intent to deter such monopolistic practices and reinforce the importance of individual accountability in maintaining market competition [2][9][10] Group 3 - The case serves as a precedent for future enforcement actions, indicating that anti-monopoly responsibilities will not be limited to corporate entities but will also encompass key individuals involved in orchestrating such agreements [10][12] - The recent amendments to the Anti-Monopoly Law, particularly the inclusion of provisions targeting individuals who organize or assist in forming monopoly agreements, aim to close loopholes that previously allowed key actors to evade responsibility [12][13] - The implications of this case extend to the broader regulatory landscape, suggesting a more rigorous approach to monitoring and penalizing anti-competitive behavior in sensitive industries such as pharmaceuticals [19]

Core Viewpoint - The enforcement of antitrust laws in the pharmaceutical sector is crucial for maintaining fair competition, ensuring effective drug supply, and protecting patient rights, as demonstrated by the recent administrative penalties exceeding 360 million yuan against four companies involved in price-fixing agreements [1][2]. Group 1: Antitrust Enforcement Actions - The Tianjin Municipal Market Supervision Administration has imposed penalties on four major domestic producers of sodium dehydrocholate, which is essential for producing sodium dehydrocholate injection, for engaging in a price-fixing agreement that disrupted market competition and increased drug prices [2][3]. - The organizer of the price-fixing scheme, identified as Guo, was subjected to a fine of 5 million yuan, highlighting the focus on punishing not just the companies but also the individuals orchestrating such anticompetitive behaviors [3][4]. Group 2: Penalties and Compliance - The four companies were fined 8% of their previous year's sales revenue, reflecting the seriousness of antitrust enforcement and serving as a deterrent against future violations [4][5]. - Individual penalties were also imposed on key personnel from the involved companies, reinforcing the principle of personal accountability in antitrust violations [5][6]. Group 3: Market Impact and Benefits - The enforcement actions are expected to restore competition in the sodium dehydrocholate market, encouraging companies to innovate and improve product quality while reducing costs [10][11]. - The reduction in raw material prices is anticipated to lower production costs for sodium dehydrocholate formulations, benefiting national healthcare and patients by alleviating financial burdens [11][12]. Group 4: Regulatory Improvements - The case emphasizes the need for enhanced regulatory oversight across the pharmaceutical supply chain, including production and sales, to prevent future monopolistic practices [14][15]. - Strengthening investigation and evidence-gathering capabilities is essential for effective antitrust enforcement, ensuring that regulatory bodies can address increasingly complex anticompetitive behaviors [15][16]. - The case also highlights the necessity for refining legal frameworks and enforcement standards to improve transparency and predictability in antitrust actions [16].

天津市市场监管委依法作出行政处罚决定：对自然人郭某某顶格处以罚款500万元；对四家企业没收违 法所得，并分别处上一年度销售额8%的罚款，合计3.54亿元；对四家企业中对于达成垄断协议负有个 人责任的四名责任人员分别处以60万元罚款。 编辑：韩娇娇 近日，根据总局指定管辖，天津市市场监管委依法对郭某某组织津药药业股份有限公司、浙江仙琚制药 股份有限公司、江苏联环药业股份有限公司和西安国康瑞金制药有限公司四家企业达成并实施垄断协议 案作出行政处罚。 经查，2021年11月起，自然人郭某某通过沟通联络、组织聚会、实地走访等方式，与四家企业相关人员 商讨提高地塞米松磷酸钠原料药价格，达成停止价格竞争、共同涨价的协议，四家企业随后同步停止对 外供货，造成市场供应紧张，并按照协议共同提高价格。2022年2月至2024年3月，四家企业将地塞米松 磷酸钠原料药销售价格从每公斤8000元上涨到1.3万元，排除、限制了市场竞争，进一步抬高地塞米松 磷酸钠制剂价格，直接推高医保负担与患者成本，损害消费者合法权益和社会公共利益。 另外，今年3月，相关部门依法对甲硫酸新斯的明注射液垄断案涉嫌企业罚没合计2.23亿元，并首次对 有关人员 ...

齐鲁晚报·齐鲁壹点 李牧青 6月10日晚间，联环药业（600513.SH）发布公告称，公司于近日收到天津市市场监督管理委员会下发的《行政处罚决定书》（津市监垄处[2025]5号）。监 管部门认为，公司与具有竞争关系的经营者以垄断协议形式变更、固定地塞米松磷酸钠原料药价格，排除、限制了地塞米松磷酸钠原料药销售领域的竞争， 违反了"反垄断法"相关规定；责令公司停止违法行为，并合计罚没约6103.82万元。 关于这一金额，联环药业表示，本次罚没金额占公司合并报表范围最近一个会计年度经审计的营业收入和归属净利润的比例分别为 2.83% 和 72.53%。 联环药业披露2024年年度报告显示，2024年公司实现营业总收入21.60亿元，同比下降0.63%；归母净利润8416.00万元，同比下降37.66%；扣非净利润 4986.80万元，同比下降56.89%。 关于其公司本期净利润下降29.69%，归母净利润下降37.66%，联环药业称，主要由于研发投入大幅增长，此外，部分子公司研发投入较多，较上年投资收 益减少。同时受医保政策、市场需求变化和市场结构调整等综合因素影响，期间费用上涨，主要系人工薪酬以及市场服务费增加。 ...

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. was fined approximately 61.04 million yuan for violating the Anti-Monopoly Law during the sale of the raw material dexamethasone phosphate sodium, marking a significant enforcement action under the revised law [1][2][4][5]. Summary by Relevant Sections Administrative Penalties - The total fines from this series of cases exceed 360 million yuan, with Lianhuan Pharmaceutical's fine being a substantial part of this total [7]. - Lianhuan Pharmaceutical was fined 61.04 million yuan, which includes the confiscation of illegal gains of 17.89 million yuan and a fine of approximately 43.14 million yuan based on 8% of its 2023 sales [4][8]. Case Background - The case involved four pharmaceutical companies colluding to raise prices of dexamethasone phosphate sodium, a critical drug for treating severe COVID-19 cases, leading to increased costs for patients and healthcare systems [8][10]. - The collusion lasted for about two and a half years, starting from November 20, 2021, when the agreement was made during a meeting organized by an individual named Guo [8][21]. Enforcement Trends - The case highlights a trend of stricter enforcement of anti-monopoly laws, particularly in the pharmaceutical sector, where raw material monopolies have become a focus for regulatory bodies [10][11]. - The penalties reflect a dual approach of strict punishment for violations and incentives for compliance, as seen in the differentiated penalties based on cooperation with investigations [13][14]. Implications for the Industry - The case serves as a warning for pharmaceutical companies regarding the risks of horizontal agreements and the need for comprehensive compliance systems to prevent anti-competitive behavior [14]. - Companies are encouraged to establish internal reporting mechanisms and crisis response strategies to mitigate risks associated with anti-monopoly violations [14].

以下文章来源于21新健康 ，作者李佳英 21新健康 . 21世纪传媒 · 公众号矩阵成员。 编 辑丨季媛媛 图 源丨图虫 原料药领域又现垄断案。 近日，联环药业称收到天津市场监管委员会的《行政处罚决定书》， 因操纵地塞米松磷酸钠 原料药价格，被罚没6103.82万元，占其2024年净利润的72.53% 。而就在近期，津药药业、 仙琚制药也因同一垄断行为被重罚， 三家企业罚没总额高达3.26亿元 。 涉事药企表示将立即组织整改，终止相关不当行为，并积极主动向客户寄送《调价通知函》 。 这场风暴涉及的地塞米松，曾被列入《新型冠状病毒感染的肺炎诊疗方案》。然而，根据公开 信息， 其价格曾从0.35元/支暴涨至98.76元/支，涨幅高达282倍 。 相 关 处 罚 决 定 书 披 露 了 背 后 的 垄 断 手 法 ： 多 家 药 企 及 相 关 人 员 不 仅 达 成 " 停 止 价 格竞争、共同涨价"的口头协议，还通过商业公司"兜底采购"确保垄断实施。 "津药药业、联环药业、西安国康瑞金和仙琚制药这四家企业的行为属于典型的串通涨价。"北 京市京都律师事务所反垄断部主管合伙人、耀时跨境合规研究院研究员金毅向21世纪 ...

联环药业表示，本次罚没金额占公司合并报表范围最近一个会计年度经审计的营业收入和归属净利润的 比例分别为2.83%和72.53%。上述罚没款金额将相应减少公司2025年度归属净利润6103.82万元。 地塞米松磷酸钠是一种肾上腺皮质激素类药物，具有抗炎、抗过敏、抗风湿、免疫抑制作用，因被证明 对新冠肺炎重症患者有疗效，被编入国内《新型冠状病毒肺炎诊疗方案》（第九版、第十版）推荐用 药，用于重症新冠肺炎临床治疗。 地塞米松原料药垄断案终于尘埃落定。6月11日，江苏联环药业股份有限公司（简称"联环药业"）收到 天津市市场监督管理委员会下发的《行政处罚决定书》，责令其停止违法行为，并处罚款合计6103.82 万元。此前，一同实施垄断的津药药业、仙琚制药也已收到《行政处罚决定书》。而此次被罚没的金 额，占据联环药业去年超七成的净利润。 三家药企累计被罚3.26亿元 根据《行政处罚决定书》，天津市市场监督管理委员会认为，联环药业与具有竞争关系的经营者，以垄 断协议形式变更、固定地塞米松磷酸钠原料药价格，排除、限制了地塞米松磷酸钠原料药销售领域的竞 争，违反了《中华人民共和国反垄断法》相关规定，属于达成并实施"固定或者变更 ...

在2025年6月10日于印度尼西亚商业竞争监督委员会（KPPU）办公室举行的听证会上，TikTok方面对垄断质疑进行了有力回应。TikTok法律顾问 FaridFauziNasution表示，Tokopedia和ShopTokopedia平台上的销售行为严格遵循现行法规。 他指出，这两大平台与多家物流和支付服务提供商建立了合作关系，其中大多数合作伙伴也同时服务于印尼其他电商平台。这意味着市场上的物流和支付 服务并非被单一平台垄断，而是处于开放竞争的状态。 TikTok回应收购Tokopedia股份：合规运营，无垄断之虞 据tempo.co报道，TikTokNusantara(SG)Pte.Ltd.否认其收购PTTokopedia股份后存在垄断行为的指控。此前，商业竞争监督委员会(KPPU)在对这笔电商股份 收购交易进行全面评估后，提出了存在垄断的可能性。 2024年1月31日，TikTokNusantara(SG)Pte.Ltd.成功收购了PTTokopedia75.01%的股份。Tokopedia作为印尼本土电商领域的佼佼者，拥有庞大的用户群体和 可观的市场份额。而TikTok凭借其全球知名的社交媒体平台地 ...

Core Insights - Tencent Music Entertainment Group announced a merger agreement with Ximalaya for a total consideration of approximately $12.6 billion in cash and stock, making it one of the most significant acquisitions in the Chinese internet sector in recent years [2] - Post-acquisition, Ximalaya will operate as a wholly-owned subsidiary of Tencent Music, maintaining its brand and operational independence [2][4] - The merger is expected to create a dominant player in the music and audio content market, consolidating Tencent Music's existing platforms and significantly increasing its market share [4][5] Company Overview - Tencent Music has been a leader in the digital music market since its establishment in 2016, with a steady increase in market share and profits [4] - Ximalaya holds a dominant position in the online audio sector, with a user penetration rate of 77.8% and over 60% of total listening time among audio users [4][5] - The merger will combine Tencent Music's younger user demographic with Ximalaya's broader age coverage, enhancing user engagement and monetization opportunities [5][6] Market Impact - The merger is likely to reshape the competitive landscape of the online audio industry, potentially leading to a monopolistic environment that could stifle innovation and limit choices for users and creators [5][15] - The combined entity will have unprecedented control over user engagement, content resources, and creator relationships, which may lead to increased market concentration and reduced competition [7][15] - Concerns have been raised regarding the potential for anti-competitive behavior, given Tencent's history with regulatory scrutiny over past acquisitions [8][12] Regulatory Considerations - The merger may trigger regulatory scrutiny due to the high market concentration it creates, reminiscent of previous investigations into Tencent's business practices [8][13] - The potential for anti-competitive practices could lead to increased oversight from regulatory bodies, especially considering Tencent's past violations of antitrust laws [9][12] User and Creator Implications - The merger could negatively impact content creators by reducing their negotiating power and limiting their options for collaboration, potentially leading to a decrease in income and opportunities [17][20] - Users may face higher prices and reduced access to content as the merged entity seeks to maximize profits, which could diminish the overall user experience [20][23] - The consolidation of power may lead to a homogenization of content, reducing diversity and innovation in the audio and music sectors [19][23]